For the quarter ending 2026-03-31, HCAT had $9,050K increase in cash & cash equivalents over the period. $18,173K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Impairment of long-lived assets | - | - | 6,900 | 0 |
| Net loss | -111,026 | -91,025 | -22,229 | -64,720 |
| Stock-based compensation expense | 3,770 | 4,107 | 7,039 | 15,866 |
| Impairment of long-lived assets | - | 6,900 | - | - |
| Depreciation and amortization | 12,115 | 12,882 | 12,614 | 25,004 |
| Change in fair value of contingent consideration liabilities | - | 0 | -1,895 | -5,168 |
| Non-cash operating lease expense | -625 | -699 | -747 | -1,484 |
| Amortization of debt discount, issuance costs, and deferred financing costs | 633 | 819 | 817 | 2,089 |
| Investment discount and premium accretion | 227 | 287 | 345 | 933 |
| Provision for expected credit losses | 555 | 93 | 300 | 1,110 |
| Deferred tax provision | 44 | 195 | 43 | -157 |
| Impairment of goodwill and intangible assets | - | 110,223 | - | - |
| Impairment of goodwill | 66,732 | - | 0 | 28,769 |
| Other | 229 | -19 | 374 | -784 |
| Accounts receivable, net | 591 | -900 | -7,924 | 10,633 |
| Prepaid expenses and other assets | 33 | 365 | 534 | -2,468 |
| Accounts payable, accrued liabilities, and other liabilities | 4,407 | 4,217 | -3,091 | -12,638 |
| Deferred revenue | 13,452 | -2,697 | -8,119 | 11,423 |
| Operating lease liabilities | -943 | -1,061 | -1,009 | -1,897 |
| Net cash provided by operating activities | 18,511 | 9,912 | -464 | -8,717 |
| Proceeds from the sale and maturity of short-term investments | 21,000 | 14,500 | 6,240 | 143,208 |
| Purchase of short-term investments | 24,915 | 7,908 | 10,464 | 46,760 |
| Acquisition of businesses, net of cash acquired | 0 | 0 | 0 | 41,114 |
| Capitalization of internal-use software | 4,604 | 5,142 | 4,552 | 10,086 |
| Purchase of property and equipment | 338 | 273 | 255 | 440 |
| Purchase of intangible assets | 553 | 181 | 328 | 296 |
| Proceeds from the sale of property and equipment | 4 | 13 | 6 | 25 |
| Net cash (used in) provided by investing activities | -9,406 | 1,009 | -9,353 | 44,537 |
| Proceeds from issuance of long-term debt, net of issuance costs | - | 0 | 0 | - |
| Payment of deferred financing costs | - | 0 | 0 | - |
| Proceeds from exercise of stock options | - | 0 | 0 | 0 |
| Proceeds from employee stock purchase plan | 403 | -27 | 534 | 1,003 |
| Repurchase of common stock | 0 | 0 | 0 | 5,000 |
| Repayment of debt | 407 | 407 | 1,071 | 230,814 |
| Net cash used in financing activities | -4 | -434 | -537 | -234,811 |
| Effect of exchange rate changes on cash and cash equivalents | -51 | 22 | -53 | 58 |
| Net increase in cash and cash equivalents | 9,050 | 10,509 | -10,407 | -198,933 |
| Cash and cash equivalents at beginning of period | 50,814 | 40,305 | 249,645 | - |
| Cash and cash equivalents at end of period | 59,864 | 50,814 | 40,305 | - |
Health Catalyst, Inc. (HCAT)
Health Catalyst, Inc. (HCAT)